UPDATE - Breathtec Biomedical Commences Trading on the Canadian Securities Exchange (CSE: BTH)

VANCOUVER, BC--(Marketwired - Feb 1, 2016) - Breathtec Biomedical Inc. (CNSX: BTH) (CSE: BTH) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to announce that the Company expects to start trading on the Canadian Securities Exchange (the "Exchange") on Monday, February 1, 2016 under the symbol "BTH".

Breathtec will be focusing its efforts to develop hand held breath testing and analysis tools for the early detection of infections, diabetes, and certain types of cancer.

"A disruptive technology is an innovation that eventually overturns the status quo and forever changes the future. Breathtec is aiming to change the world of medical diagnostics with the development of hand held breath testing devices that will change the way doctors detect diseases," said Kal Malhi, President of Breathtec. "Breathtec has a very strong partnership with the University of Florida and is also currently evaluating several other breath testing technologies from around the world to add to our intellectual property portfolio. We are excited to begin trading as a public company in Canada." 

To date the Company has raised CAD $3.4 million that will be utilized to develop breath analysis diagnostic devices and pursue similar technologies.

Capital Markets Advisory
In related news, Breathtec is pleased to announce that it has retained Core Capital Partners to provide capital markets advisory. Core Capital provides capital raising, advisory and deal structure advice to emerging Health Care and Technology companies. Core specializes in funding early stage, high-growth ideas via a public equity approach. Core has an unmatched access to capital, ability to identify opportunities and accelerate transactions and corporate developments.

Under the terms of the agreement, with an effective date of February 1, 2016, Core Capital will receive compensation of $5,000 per month. Subject to approval from the Canadian Securities Exchange ("CSE") Core Capital will also receive 400,000 options exercisable at a price of $0.25 per share until February 1, 2021.

ON BEHALF OF THE BOARD
"Kal Malhi"
President & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to the completion of the listing of the Company's shares on the Canadian Securities Exchange and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.